Immunomedics receives US patent for protein therapeutic manufacturing

The patent named ‘Mammalian cell lines for increasing longevity and protein yield from a cell culture’ provides coverage until 2025.

It covers improved cell lines of greater longevity, allowing increased production of recombinant proteins such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, erythropoietin, thrombopoietin, hormones, and vaccines.

Immunomedics president and CEO Cynthia L Sullivan said the company is glad to have received the new patent.

"The new technology has already been incorporated into the manufacture of all of our new protein drug candidates, including all of our Dock-and-Lock generated protein constructs that are in preclinical development," Sullivan added.